Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Calhex 231 hydrochloride is a CaSR inhibitor with the potential for diabetic cardiomyopathy treatment. It blocks Ca2+-induced accumulation of [3H]inositol phosphate (IC50: 0.39 μM in HEK293 cells).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 88.00 | |
5 mg | 5 days | $ 148.00 |
Description | Calhex 231 hydrochloride is a CaSR inhibitor with the potential for diabetic cardiomyopathy treatment. It blocks Ca2+-induced accumulation of [3H]inositol phosphate (IC50: 0.39 μM in HEK293 cells). |
Targets&IC50 | CaSR:0.39 μM |
In vitro | Calhex 231 could inhibit Itch (atrophin-1 interacting protein 4)-ubiquitin proteasome and TGF-β1/Smads pathways, and then depress the proliferation of cardiac fibroblasts, along with the reduction deposition of collagen, alleviate glucose-induced myocardial fibrosis. Calhex 231 treatment significantly downregulates the CaSR, α-SMA, Col-I/III, MMP2/9 expresses. Calhex231 alleviates high glucose-induced myocardial fibrosis in cardiac fibroblasts [1]. |
In vivo | In the type 1 diabetic model (T1D) rats, Calhex 231 (4.07 mg/kg; i.p.; daily; for 12 weeks; male Wistar rats) treatment ameliorates diabetic myocardial fibrosis [1]. |
Molecular Weight | 443.41 |
Formula | C25H28Cl2N2O |
CAS No. | 2387505-78-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Calhex 231 hydrochloride 2387505-78-2 GPCR/G Protein CaSR Calhex 231 Hydrochloride inhibitor inhibit